MX366910B - Metodos de fabricacion para controlar el contenido de lisina c-terminal, galactosa y acido sialico en proteinas recombinantes. - Google Patents

Metodos de fabricacion para controlar el contenido de lisina c-terminal, galactosa y acido sialico en proteinas recombinantes.

Info

Publication number
MX366910B
MX366910B MX2015012361A MX2015012361A MX366910B MX 366910 B MX366910 B MX 366910B MX 2015012361 A MX2015012361 A MX 2015012361A MX 2015012361 A MX2015012361 A MX 2015012361A MX 366910 B MX366910 B MX 366910B
Authority
MX
Mexico
Prior art keywords
sialic acid
acid content
galactose
terminal lysine
control
Prior art date
Application number
MX2015012361A
Other languages
English (en)
Other versions
MX2015012361A (es
Inventor
Marcel Flikweert
Charles Goochee
Francis Maslanka
Franciscus Johannes Ignatius Nagel
James Ryland
Eugene Schafer
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX366910(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2015012361A publication Critical patent/MX2015012361A/es
Publication of MX366910B publication Critical patent/MX366910B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)

Abstract

La presente invención se refiere a un método para producir un anticuerpo, como un anticuerpo anti-TNFa (por ejemplo, infliximab) que tiene un contenido de lisina en el extremo C terminal de aproximadamente 20% a aproximadamente 70%, y un contendido de ácido siálico de aproximadamente 1% a aproximadamente 20%, que comprende cultivar una célula huésped sensible al zinc transfectada con ADN que codifica el anticuerpo en un medio de cultivo que comprende por lo menos 0.5 µM de zinc; y controlar la concentración de zinc en el medio de cultivo, para producir así el anticuerpo.
MX2015012361A 2013-03-15 2014-03-07 Metodos de fabricacion para controlar el contenido de lisina c-terminal, galactosa y acido sialico en proteinas recombinantes. MX366910B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791094P 2013-03-15 2013-03-15
PCT/US2014/021574 WO2014149935A1 (en) 2013-03-15 2014-03-07 Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins

Publications (2)

Publication Number Publication Date
MX2015012361A MX2015012361A (es) 2016-04-28
MX366910B true MX366910B (es) 2019-07-30

Family

ID=51528780

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012361A MX366910B (es) 2013-03-15 2014-03-07 Metodos de fabricacion para controlar el contenido de lisina c-terminal, galactosa y acido sialico en proteinas recombinantes.

Country Status (26)

Country Link
US (3) US20140273092A1 (es)
EP (1) EP2970980B2 (es)
JP (1) JP2016512029A (es)
KR (1) KR102216003B1 (es)
CN (1) CN105378086B (es)
AR (2) AR095660A1 (es)
AU (2) AU2014237635B2 (es)
BR (1) BR112015022971B1 (es)
CA (1) CA2907140A1 (es)
CY (1) CY1120980T1 (es)
DK (1) DK2970980T3 (es)
EA (1) EA201591807A1 (es)
ES (1) ES2690047T3 (es)
HR (1) HRP20181741T1 (es)
IL (1) IL240689B (es)
LT (1) LT2970980T (es)
MX (1) MX366910B (es)
PH (1) PH12015501837A1 (es)
PL (1) PL2970980T3 (es)
PT (1) PT2970980T (es)
RS (1) RS57791B1 (es)
SG (1) SG11201507577RA (es)
SI (1) SI2970980T1 (es)
TW (1) TWI630216B (es)
WO (1) WO2014149935A1 (es)
ZA (1) ZA201507671B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
AU2014237635B2 (en) * 2013-03-15 2020-03-12 Janssen Biologics B.V. Manufacturing methods to control C-terminal lysine, galactose and sialic acid content in recombinant proteins
WO2015024977A1 (en) 2013-08-20 2015-02-26 Lek Pharmaceuticals D.D. CELL CULTURE MEDIUM AND PROCESS FOR CONTROLLING α-AMIDATION AND/OR C-TERMINAL AMINO ACID CLEAVAGE OF POLYPEPTIDES
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
BR112018008891A8 (pt) 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
WO2017083224A1 (en) * 2015-11-09 2017-05-18 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
BR112018012344A2 (pt) 2015-12-17 2018-12-04 Janssen Biotech Inc anticorpos que se ligam especificamente a hla-dr e seus usos
KR102587941B1 (ko) 2016-08-12 2023-10-11 얀센 바이오테크 인코포레이티드 향상된 효능작용 및 이펙터 기능을 갖는 조작된 항체 및 다른 Fc-도메인 함유 분자
EP3497126A4 (en) 2016-08-12 2020-04-08 Janssen Biotech, Inc. ANTIBODIES OF FC MODIFIED ANTI-TNFR SUPERFAMILY HAVING IMPROVED AGONIST ACTIVITY AND METHODS OF USE THEREOF
CA3065516A1 (en) 2017-06-05 2018-12-13 Janssen Biotech, Inc. Antibodies that specifically bind pd-1 and methods of use
CA3065171A1 (en) 2017-06-05 2018-12-13 Janssen Biotech, Inc. Engineered multispecific antibodies and other multimeric proteins with asymmetrical ch2-ch3 region mutations
WO2019077628A1 (en) * 2017-10-16 2019-04-25 Council Of Scientific & Industrial Research ZINC SUPPLEMENTATION TO DECREASE GALACTOSYLATION OF RECOMBINANT GLYCOPROTEINS
MA52772A (fr) 2018-05-24 2021-04-14 Janssen Biotech Inc Anticorps anti-tmeff2 monospécifiques et multispécifiques et leurs utilisations
US20220033487A1 (en) * 2018-12-31 2022-02-03 Momenta Pharmaceuticals, Inc. Methods of Producing Ustekinumab
UY38803A (es) 2019-07-26 2021-01-29 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y usos de las mismas
CA3148121A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Materials and methods for improved single chain variable fragments
PE20230001A1 (es) 2020-03-13 2023-01-05 Janssen Biotech Inc Materiales y metodos para la union de siglec-3/cd33
CA3184189A1 (en) 2020-05-27 2021-12-02 Janssen Biotech, Inc. Proteins comprising cd3 antigen binding domains and uses thereof
CA3190307A1 (en) 2020-07-29 2022-02-03 Janssen Biotech, Inc. Proteins comprising hla-g antigen binding domains and their uses
UY39467A (es) 2020-10-13 2022-04-29 Janssen Biotech Inc Inmunidad mediada por células t de bioingeniería, materiales y otros métodos para modular el grupo de diferenciación iv y / o viii
WO2022084915A1 (en) 2020-10-22 2022-04-28 Janssen Biotech, Inc. Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
KR20230137393A (ko) 2021-01-28 2023-10-04 얀센 바이오테크 인코포레이티드 Psma 결합 단백질 및 이의 용도
EP4314056A1 (en) 2021-03-24 2024-02-07 Janssen Biotech, Inc. Proteins comprising cd3 antigen binding domains and uses thereof
TW202304986A (zh) 2021-03-24 2023-02-01 美商健生生物科技公司 靶向cd22及cd79b的抗體
KR20240055002A (ko) 2021-09-13 2024-04-26 얀센 바이오테크 인코포레이티드 암 치료를 위한 CD33 x Vδ2 다중특이성 항체
WO2023046322A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
WO2023089587A1 (en) 2021-11-22 2023-05-25 Janssen Biotech, Inc. Compositions comprising enhanced multispecific binding agents for an immune response
WO2024089551A1 (en) 2022-10-25 2024-05-02 Janssen Biotech, Inc. Msln and cd3 binding agents and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
EP0288088B1 (en) 1987-04-24 1994-03-09 Teijin Limited Detection of tumor necrosis factor; monoclonal antibody and kit
JP3443119B2 (ja) 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
DK1097945T3 (da) 1991-03-18 2007-11-05 Univ New York Monoklonale og kimære antistoffer, der er specifikke for human tumornekrosefaktor
FR2807767B1 (fr) † 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
CA2450289A1 (en) † 2003-03-20 2005-05-19 Imclone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
US20040185047A1 (en) 2003-03-21 2004-09-23 Jill Giles-Komar Anti- TNF antibodies, compositions, methods and uses
CA2583027A1 (en) † 2004-11-02 2006-10-19 Ares Trading S.A. Serum-free cell culture medium for mammalian cells
EP2283043B1 (en) * 2008-04-07 2014-08-13 Bayer HealthCare, LLC Methods of recombinant production of glycoproteins
DK2702164T3 (en) * 2011-04-29 2016-02-01 Biocon Res Ltd METHOD FOR REDUCING heterogeneity OF ANTIBODIES AND METHOD OF PRODUCING THESE ANTIBODIES
US9475858B2 (en) 2011-07-08 2016-10-25 Momenta Pharmaceuticals, Inc. Cell culture process
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
AU2014237635B2 (en) * 2013-03-15 2020-03-12 Janssen Biologics B.V. Manufacturing methods to control C-terminal lysine, galactose and sialic acid content in recombinant proteins

Also Published As

Publication number Publication date
SG11201507577RA (en) 2015-10-29
US11149085B2 (en) 2021-10-19
CN105378086B (zh) 2019-05-28
WO2014149935A1 (en) 2014-09-25
ZA201507671B (en) 2017-11-29
AU2014237635B2 (en) 2020-03-12
AU2014237635A1 (en) 2015-09-03
EA201591807A1 (ru) 2016-02-29
US20140273092A1 (en) 2014-09-18
ES2690047T3 (es) 2018-11-19
US20160237149A1 (en) 2016-08-18
RS57791B1 (sr) 2018-12-31
EP2970980A4 (en) 2016-09-07
EP2970980B1 (en) 2018-08-15
TWI630216B (zh) 2018-07-21
AU2020203864B2 (en) 2022-05-26
AR095660A1 (es) 2015-11-04
EP2970980A1 (en) 2016-01-20
PL2970980T3 (pl) 2019-01-31
PH12015501837B1 (en) 2015-11-09
TW201441263A (zh) 2014-11-01
SI2970980T1 (sl) 2018-11-30
BR112015022971B1 (pt) 2022-05-17
BR112015022971A2 (pt) 2017-11-14
EP2970980B2 (en) 2022-07-27
IL240689A0 (en) 2015-10-29
KR20150129025A (ko) 2015-11-18
LT2970980T (lt) 2018-10-25
CA2907140A1 (en) 2014-09-25
CY1120980T1 (el) 2019-12-11
US20220089712A1 (en) 2022-03-24
JP2016512029A (ja) 2016-04-25
MX2015012361A (es) 2016-04-28
HRP20181741T1 (hr) 2018-12-28
PT2970980T (pt) 2018-11-19
IL240689B (en) 2021-12-01
PH12015501837A1 (en) 2015-11-09
KR102216003B1 (ko) 2021-02-16
AR124871A2 (es) 2023-05-17
CN105378086A (zh) 2016-03-02
AU2020203864A1 (en) 2020-07-02
DK2970980T3 (en) 2018-10-22

Similar Documents

Publication Publication Date Title
MX366910B (es) Metodos de fabricacion para controlar el contenido de lisina c-terminal, galactosa y acido sialico en proteinas recombinantes.
MX2018002121A (es) Elaboracion de fosfatasas alcalinas.
MX2020011334A (es) Cultivo celular metabolicamente optimizado.
SG10201901417UA (en) Production of proteins in glutamine-free cell culture media
PH12018501282A1 (en) Anti-c5 antibodies and methods of use
NZ605403A (en) Method of producing recombinant adamts13 in cell culture
EA201001435A1 (ru) Клетка, ферментирующая сахар-пентозу
MX2023001360A (es) Anticuerpos anti-c5 y metodos de uso.
MX348739B (es) Metodo para purificar soluciones de inmunoglobulina.
NZ602958A (en) High level expression of recombinant toxin proteins
MY181513A (en) Cell culture compositions and methods for polypeptide production
IN2015DN02771A (es)
NZ705575A (en) Recombinant clostridium botulinum neurotoxins
IN2014CN03077A (es)
BR112015007319A2 (pt) composições e métodos para produzir glicoproteínas
MX2016007207A (es) Metodos mejorados para la produccion de polipeptidos recombinantes.
IN2014DN00094A (es)
AR086200A1 (es) Hongos filamentosos que tienen un fenotipo de viscosidad alterado
WO2013163654A3 (en) Nucleic acids, cells, and methods for producing secreted proteins
MY184387A (en) Improved surface display of functional proteins in a broad range of gram negative bacteria
EA201000945A1 (ru) Конструирование системы секреции на основе sm-белков
MX2015010887A (es) Formulaciones y metodos para aumentar la produccion de proteinas recombinantes.
MX2017008633A (es) Procedimiento para preparar una proteina de fusion tnfr-fc que contiene un contenido objetivo de impurezas.
MX2014012407A (es) Metodo para incrementar la secrecion de proteinas recombinantes.
MY170261A (en) Compositions and methods of producing enterokinase in yeast ian fotheringham and peter j. sheffield

Legal Events

Date Code Title Description
FG Grant or registration